Clinical Trial Detail

NCT ID NCT02760030
Title Fulvestrant and Palbociclib in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Ohio State University Comprehensive Cancer Center
Indications

Her2-receptor negative breast cancer

Therapies

Fulvestrant + Palbociclib

Age Groups: senior

Additional content available in CKB BOOST